Belpointe Asset Management LLC Lowers Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Belpointe Asset Management cut its Johnson & Johnson stake by 24.2% in Q4, selling 4,777 shares and leaving 14,996 shares valued at about $3.10 million.
• Insider selling activity is notable: EVP Vanessa Broadhurst sold 6,197 shares and EVP Timothy Schmid sold 1,322 shares, with insiders offloading 30,142 shares over the past 90 days while owning just 0.16% of the company.
• Corporate results and shareholder actions: J&J beat Q1 estimates (EPS $2.70 vs $2.68; revenue $24.06B vs $23.60B), set FY2026 guidance of $11.45–$11.65 EPS, and raised its quarterly dividend to $1.34 (annual $5.36, ~2.3% yield).

Belpointe Asset Management LLC cut its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 24.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,996 shares of the company's stock after selling 4,777 shares during the quarter. Belpointe Asset Management LLC's holdings in Johnson & Johnson were worth $3,104,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in JNJ. Hudson Edge Investment Partners Inc. lifted its position in shares of Johnson & Johnson by 2.5% during the 4th quarter. Hudson Edge Investment Partners Inc. now owns 43,706 shares of the company's stock valued at $9,045,000 after buying an additional 1,054 shares in the last quarter. Beacon Bridge Wealth Partners LLC increased its holdings in Johnson & Johnson by 8.6% in the 4th quarter. Beacon Bridge Wealth Partners LLC now owns 1,605 shares of the company's stock worth $332,000 after acquiring an additional 127 shares in the last quarter. Earned Wealth Advisors LLC increased its holdings in Johnson & Johnson by 96.0% in the 4th quarter. Earned Wealth Advisors LLC now owns 9,224 shares of the company's stock worth $1,909,000 after acquiring an additional 4,517 shares in the last quarter. Berkshire Money Management Inc. acquired a new position in Johnson & Johnson during the fourth quarter worth $339,000. Finally, BigSur Wealth Management LLC lifted its holdings in Johnson & Johnson by 1.4% during the fourth quarter. BigSur Wealth Management LLC now owns 5,608 shares of the company's stock valued at $1,161,000 after purchasing an additional 76 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Long‑term Phase 3 and open‑label extension data for IMAAVY (nipocalimab) showed sustained disease control and safety through ~120 weeks in generalized myasthenia gravis; J&J also started the first industry head‑to‑head FcRn study — these clinical wins strengthen JNJ’s immunology franchise and future revenue potential. IMAAVY press release
• Positive Sentiment: New AI and EP (electrophysiology) product updates — including the CARTOSOUND SONATA AI module and expanded VARIPULSE data — add visible growth optionality in cardiac devices and services, helping justify premium valuation for the MedTech segment. AI Cardiac Tools article
• Positive Sentiment: Strategic commercial collaboration with Viz.ai to deploy AI subdural hemorrhage detection across U.S. hospitals broadens J&J’s neurovascular offering and supports recurring software/solution revenue opportunities. Viz.ai collaboration
• Positive Sentiment: CE Mark approval for the new ETHICON 4000 surgical stapler is a commercial milestone that supports device sales growth in Europe and enhances the surgical portfolio’s near‑term revenue trajectory. ETHICON 4000 CE Mark
• Positive Sentiment: Technical and sentiment catalysts: Seeking Alpha notes JNJ snapped a six‑session losing streak, and high‑profile endorsements / analyst attention (including Jim Cramer buys and a Guggenheim mention) are drawing retail and institutional interest. Seeking Alpha: snap losses Jim Cramer mention Guggenheim analyst note
• Neutral Sentiment: Coverage pieces highlight JNJ as a defensive/dividend and counter‑cyclical pick, which can attract income‑oriented buyers but is a longer‑term narrative rather than an immediate catalyst. Dividend stocks article Counter cyclical article

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the company's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares in the company, valued at $5,598,700.17. This represents a 21.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy Schmid sold 1,322 shares of the firm's stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company's stock, valued at $6,251,310.02. This trade represents a 4.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Up 2.0%

JNJ stock opened at $230.67 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The firm has a 50-day moving average of $240.50 and a two-hundred day moving average of $218.19. Johnson & Johnson has a 12 month low of $146.12 and a 12 month high of $251.71. The company has a market cap of $555.60 billion, a price-to-earnings ratio of 26.67, a PEG ratio of 2.21 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.02. The business had revenue of $24.06 billion for the quarter, compared to analysts' expectations of $23.60 billion. Johnson & Johnson had a return on equity of 32.75% and a net margin of 21.83%.The business's revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, analysts forecast that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be paid a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Tuesday, May 26th. Johnson & Johnson's dividend payout ratio is presently 60.12%.

Analyst Ratings Changes

Several analysts have recently issued reports on JNJ shares. Wall Street Zen lowered shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Saturday, February 14th. Wells Fargo & Company raised their price target on shares of Johnson & Johnson from $240.00 to $263.00 and gave the company an "overweight" rating in a research note on Wednesday, April 15th. The Goldman Sachs Group lifted their price objective on Johnson & Johnson from $265.00 to $275.00 and gave the stock a "buy" rating in a report on Wednesday, April 15th. Morgan Stanley set a $283.00 price objective on Johnson & Johnson in a research note on Wednesday, April 15th. Finally, Rothschild & Co Redburn raised their target price on Johnson & Johnson from $180.00 to $210.00 and gave the company a "neutral" rating in a research report on Thursday, February 19th. Eighteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average target price of $252.48.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.